Uquifa.SA and Synthetics International. AG. announce the creation of a joint venture company to deliver the combined benefits of Synthetics and Uquifa to the global Custom Synthesis and Generic markets.
The new company will be based in Basel, Switzerland and named Synthetics-Uquifa.AG. Over the last 12 months Synthetics and Uquifa have been collaborating on the manufacture and development of a range of API’s and advanced intermediates across its manufacturing sites in Qiwei, China, Barcelona, Spain and Cuernavaca, Mexico.
A number of these projects have culminated in the transfer of API manufacture from Uquifa to Qiwei, China such as Minocycline and a number of development projects from Synthetics to Spain and Mexico.
The new company Chairman will be Dr Thomas Schulz of Synthetics and the Chief Executive will be Mr. Mark Robbins of Uquifa who both have over 20 years experience in the sector. Mark Robbins has stated; “Synthetics-Uquifa.AG is one of the first API/advanced intermediates manufacturing companies that can offer R+D and cGMP manufacture across three continents. The joint marketing and R+D programs will allow the global customer base to benefit from the competitive FDA approved manufacturing locations and over 1000 employees dedicated to effective and rapid response to the dynamic life science industry”. Dr Thomas Schulz believes; “Such a company having European, American and Asian sites with an experienced management team will address the development and manufacturing needs of the global pharmaceutical industry in the 21st century”.
Contact; Mark.I.Robbins. mrobbins@uquifa.com +34 934879477 Dr.Thomas Schulz Thomas.schulz@synthetics-int.com +41 795980378
